RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ultimovacs A Stock

Ultimovacs A Dividend 2024

Ultimovacs A Dividend

0 NOK

Ultimovacs A Dividend yield

Ticker

ULTI.OL

ISIN

NO0010851603

WKN

A2PKSD

How much dividend does Ultimovacs A 2024 pay?

According to the latest status from November 2024, Ultimovacs A paid a total of 0 NOK per share in dividends within the last 12 months. With the current Ultimovacs A price of 1.73 NOK, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Ultimovacs A Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Ultimovacs A Dividend Safe?

Ultimovacs A has been increasing the dividend for 0 years.

Over the past 9 years, Ultimovacs A has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Ultimovacs A's Dividend Distributions

Ultimovacs A’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Ultimovacs A's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Ultimovacs A's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Ultimovacs A’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Ultimovacs A Aktienanalyse

What does Ultimovacs A do?

Ultimovacs ASA is a Norwegian biotech company specializing in the development of cancer immunotherapies. The company was founded in 2011 by Øyvind Kongstun Arnesen and Gustav Gaudernack, and is headquartered in Oslo, Norway. Ultimovacs ASA's history began with the discovery of a unique Pep-antigene concept by founder Gustav Gaudernack. Over the years, the company has worked extensively on the development of innovative cancer immunotherapies based on stimulation of the body's immune system. Ultimovacs has developed a proprietary platform technology called UV1, based on the simple idea that the immune system can respond to certain structures known as peptides. The UV1 technology is based on synthetic peptides containing specific antigens that are widespread in many different types of cancer. Ultimovacs ASA's business model focuses on developing and bringing innovative cancer therapies to market. The company has three main research programs focusing on different types of cancer: lung cancer, mesothelioma, and prostate cancer. The lung cancer program is the most advanced and is currently in Phase IIb clinical trials. The basis for this program is the UV1 vaccine administered in combination with a checkpoint inhibitor therapy. The combination therapy was developed to boost the body's defenses against cancer growth and inhibit tumor growth. Ultimovacs' mesothelioma program was in the preclinical phase until recently, but has recently been approved to enter Phase I/II clinical trials. The mesothelioma therapy is also based on the UV1 platform, which was developed in a personalized form for this rare type of cancer. Ultimovacs' prostate cancer program is still in the preclinical phase, but promising results have already been obtained. The company has applied its UV1 technology in personalized therapy to identify and target specific antigens in prostate cancer patients. Ultimovacs ASA has also formed partnerships with other companies and institutions to combine its research and development activities. The company has collaborations with French pharmaceutical company Ipsen and a research group at the University of Oslo, among others. Overall, Ultimovacs ASA has a clear focus on developing cancer immunotherapies based on stimulating the body's own immune system. The company has developed a proprietary UV1 technology that allows it to quickly and effectively develop personalized therapies for different types of cancer. With its intensive research and collaboration with other companies and institutions, Ultimovacs will continue to strive to improve the state of immunooncology in cancer treatment. The answer is Ultimovacs ASA is a Norwegian biotech company specializing in cancer immunotherapy development. Ultimovacs A is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Ultimovacs A stock

How much dividend does Ultimovacs A pay?

Over the past 12 months, Ultimovacs A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ultimovacs A is expected to pay a dividend of 0 NOK.

What is the dividend yield of Ultimovacs A?

The current dividend yield of Ultimovacs A is .

When does Ultimovacs A pay dividends?

Ultimovacs A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ultimovacs A?

Ultimovacs A paid dividends every year for the past 0 years.

What is the dividend of Ultimovacs A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ultimovacs A located?

Ultimovacs A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ultimovacs A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ultimovacs A from 11/6/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Ultimovacs A pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Ultimovacs A in the year 2023?

In the year 2023, Ultimovacs A distributed 0 NOK as dividends.

In which currency does Ultimovacs A pay out the dividend?

The dividends of Ultimovacs A are distributed in NOK.

Andere Kennzahlen von Ultimovacs A

Our stock analysis for Ultimovacs A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ultimovacs A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.